126 related articles for article (PubMed ID: 1287269)
1. Regional vascular responses to thromboxane A2 analogue and their blockade with vapiprost, a selective thromboxane receptor blocking drug, in anesthetized dogs.
Noguchi K; Ojiri Y; Chibana T; Matsuzaki T; Sakanashi M
Jpn J Pharmacol; 1992 Dec; 60(4):341-8. PubMed ID: 1287269
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels.
Matsuzaki T; Noguchi K; Nakasone J; Uezu K; Higuchi M; Sakanashi M
Arzneimittelforschung; 1992 Nov; 42(11):1318-22. PubMed ID: 1492844
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of vapiprost on contractile responses of isolated dog renal arteries to thromboxane A2 analogue, U46619.
Sakanashi M; Matsuzaki T; Noguchi K; Nakasone J; Itomine T; Uza M; Toyama F; Higuchi M
Gen Pharmacol; 1994 Jul; 25(4):617-22. PubMed ID: 7958719
[TBL] [Abstract][Full Text] [Related]
4. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
[TBL] [Abstract][Full Text] [Related]
5. Effect of thromboxane A2 antagonist GR32191B on prostanoid and nonprostanoid receptors in the human internal mammary artery.
He GW; Yang CQ
J Cardiovasc Pharmacol; 1995 Jul; 26(1):13-9. PubMed ID: 7564353
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of glibenclamide on responses to thromboxane A2 mimic, U46619, in the pulmonary and hindquarters vascular beds of the cat.
Kaye AD; Nossaman BD; Santiago JA; DeWitt BJ; Ibrahim IN; Kadowitz PJ
Eur J Pharmacol; 1997 Dec; 340(2-3):187-93. PubMed ID: 9537814
[TBL] [Abstract][Full Text] [Related]
8. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
9. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Guth BD; Müller TH
Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
Fukuhara M; Neves LA; Li P; Diz DI; Ferrario CM; Brosnihan KB
J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
[TBL] [Abstract][Full Text] [Related]
11. Endogenous adenosine and coronary vasoconstriction in hypoperfused myocardium during exercise.
Duncker DJ; Laxson DD; Lindstrom P; Bache RJ
Cardiovasc Res; 1993 Sep; 27(9):1592-7. PubMed ID: 8287435
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery.
He GW; Yang CQ
Br J Clin Pharmacol; 1999 Aug; 48(2):207-15. PubMed ID: 10417498
[TBL] [Abstract][Full Text] [Related]
13. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Grover GJ; Schumacher WA
J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
[TBL] [Abstract][Full Text] [Related]
14. Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man.
Ritter JM; Benjamin N; Doktor HS; Barrow SE; Mant TG; Schey S; Stewart-Long P
Br J Clin Pharmacol; 1990 Apr; 29(4):431-6. PubMed ID: 2139338
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
Nossaman BD; Baber SR; Nazim MM; Detrolio JD; Kadowitz PJ
Can J Physiol Pharmacol; 2007; 85(3-4):360-71. PubMed ID: 17612645
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary vasoregulation by arginine vasopressin in conscious, halothane-anesthetized, and pentobarbital-anesthetized dogs with increased vasomotor tone.
Trempy GA; Nyhan DP; Murray PA
Anesthesiology; 1994 Sep; 81(3):632-40. PubMed ID: 8092510
[TBL] [Abstract][Full Text] [Related]
17. The thromboxane A2 mimetic U46619 worsens canine myocardial hypoperfusion during exercise in the presence of a coronary artery stenosis.
Bache RJ; Dai XZ
Cardiovasc Res; 1992 Apr; 26(4):351-6. PubMed ID: 1638566
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat.
Valentin JP; Bessac AM; Maffre M; John GW
Eur J Pharmacol; 1996 Dec; 317(2-3):335-42. PubMed ID: 8997619
[TBL] [Abstract][Full Text] [Related]
19. Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.
Cocks TM; Kemp BK; Pruneau D; Angus JA
Br J Pharmacol; 1993 Sep; 110(1):360-8. PubMed ID: 8220898
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin aerosol and inhaled nitric oxide fail to reverse pulmonary vasoconstriction induced by thromboxane analogue in dogs.
Welte M; Zwissler B; Habler O; Kleen M; Messmer K
Acta Physiol Scand; 1995 Jul; 154(3):395-405. PubMed ID: 7572237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
